Cancer treatment reviews最新文献

{"title":"T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis","authors":"Zoulikha M. Zaïr ,&nbsp;Gemma Butterworth ,&nbsp;Mariam Shalaby ,&nbsp;Eduard Oštarijaš ,&nbsp;Fiona Thisthlethwaite","doi":"10.1016/j.ctrv.2025.102991","DOIUrl":"10.1016/j.ctrv.2025.102991","url":null,"abstract":"<div><div>Engineered to activate a patient’s own immune response, T Cell Engagers (TCEs) are positioned to mediate T cell directed cytotoxicity through targeted engagement of a tumour antigen. Despite their attractive properties TCE therapies have yet to be widely used in the treatment of solid tumours with several obstacles that include adverse toxicity profiles.</div><div>This systematic review and <em>meta</em>-analysis assessed the toxicity associated with T-cell engagers (TCEs) in the treatment of solid tumours. Papers were sourced from MEDLINE, Cochrane Library, CINHL, EMBASE, Web of Knowledge, Scopus. Prevalence data from the identified primary studies was pooled using an inverse variance method with a restricted maximum likelihood estimator. Freeman-Tukey double arcsine transformation to determine toxicity prevalence and confidence intervals.</div><div>A total of 1147 publications were identified of which 30 were included for systematic review. Toxicity profiles from 17 TCEs, comprising 9 different ligands that utilised the CD3, CD40, CD28 or CD64 signalling pathways were characterised in this study. Of these studies, 21 publications were included for <em>meta</em>-analysis, focussing on four TCEs: catumaxomab, ertumaxomab, tebentafusb, and MDX-H210. Meta-analysis found that the most prevalent toxicities were gastrointestinal and inflammatory. Subgroup analysis revealed that Gastrointestinal toxicity (GI) toxicity was independent of tumour type or ligand. Cytokine Release Syndrome (CRS) is potentially being under-reported due to challenges of differentiation of CRS from other inflammatory mediated constituent symptoms, although Fc-independent TCEs were linked to lower inflammatory toxicity. The review highlights TCE-dependent toxicity profiles and highlights key features that may ameliorate TCE tolerance.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102991"},"PeriodicalIF":9.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term surveillance recommendations for young adult cancer survivors","authors":"Katharina Egger-Heidrich ,&nbsp;Franziska Wolters ,&nbsp;Mareike Frick ,&nbsp;Teresa Halbsguth ,&nbsp;Theresa Müller ,&nbsp;Hannah Woopen ,&nbsp;Kristin Tausche ,&nbsp;Diana Richter ,&nbsp;Judith Gebauer","doi":"10.1016/j.ctrv.2025.102992","DOIUrl":"10.1016/j.ctrv.2025.102992","url":null,"abstract":"<div><h3>Background</h3><div>Advancements in cancer treatment have led to increased survival rates among young adult cancer survivors (YACS). However, these individuals face unique long-term health risks, including secondary malignancies, cardiovascular disease, and psychosocial challenges. Effective long-term surveillance strategies are critical to mitigating these risks and improving health outcomes. This scoping review aims to summarize existing recommendations for long-term surveillance of YACS, identify gaps in current guidelines, and highlight areas for future research.</div></div><div><h3>Methods</h3><div>A scoping review was conducted using Pubmed focusing on peer-reviewed literature published between January 2015 and January 2025 that addresses post-treatment (&gt;5 years after diagnosis) follow-up strategies for YACS. The review synthesizes recommendations across various cancer types, treatment modalities, and long-term effects.</div></div><div><h3>Results</h3><div>The review identified 32 recommendations. Of all eligible articles initially retrieved, 169 different articles were included after screening and eligibility. Findings indicate a lack of standardized, age-specific surveillance guidelines, with most recommendations adapted from pediatric or adult oncology frameworks. Emerging evidence suggests that risk-based, personalized surveillance approaches—incorporating genetic predisposition, treatment history, and lifestyle factors—may optimize long-term health outcomes.</div></div><div><h3>Discussion</h3><div>This review underscores the need for age-appropriate, evidence-based surveillance guidelines tailored to YACS and highlights the importance of multidisciplinary care models to support survivorship. Future research should focus on developing standardized, risk-stratified surveillance protocols and evaluating their impact on health outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102992"},"PeriodicalIF":9.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144606174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications","authors":"Peng Qiu ,&nbsp;Xiaopeng Yu ,&nbsp;Fushuang Zheng ,&nbsp;Xi Gu ,&nbsp;QianQiu Huang ,&nbsp;Ke Qin ,&nbsp;Yueting Hu ,&nbsp;Bowen Liu ,&nbsp;Tianming Xu ,&nbsp;Tao Zhang ,&nbsp;Guanglei Chen ,&nbsp;Yang Liu","doi":"10.1016/j.ctrv.2025.102979","DOIUrl":"10.1016/j.ctrv.2025.102979","url":null,"abstract":"<div><div>Breast cancer is characterized by significant molecular heterogeneity; therefore, there are distinct clinical features, treatment modalities, and prognostic outcomes across its various molecular subtypes. In the era of precision medicine, liquid biopsy has emerged as a convenient and minimally invasive technique capable of dynamically representing the comprehensive tumor gene spectrum. This review systematically elaborates the clinical value of liquid biopsy as a breakthrough tool for precision diagnosis and treatment in breast cancer through dynamic detection of key biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and non-coding RNA (ncRNA). Specific genetic mutations and methylation signatures in ctDNA can be applied to early breast cancer screening, minimal residual disease monitoring, and tracking drug resistance mechanisms. CTCs enumeration (≥1/7.5 mL in early-stage cancer or ≥ 5/7.5 mL in metastatic cancer) and PD-L1 expression levels demonstrate direct correlations with prognostic stratification and the efficacy of immunotherapy. As the specificity and sensitivity of liquid biopsy continue to improve, personalized treatment strategies, informed by biomarker analysis and targeted precision therapies, have unveiled new avenues of hope for patients with breast cancer. However, several challenges persist in the practical application of liquid biopsy. Despite persistent challenges, such as insufficient standardization and difficulties in resolving low-abundance variants, future advancements should focus on multi-omics integration and AI-driven technological breakthroughs to overcome bottlenecks in clinical translation. This review summarizes cutting-edge liquid biopsy technologies for identifying clinically significant molecular biomarkers, focusing on discussing critical challenges in the strategies to advance precision oncology applications for optimized treatment guidance and disease surveillance in breast cancer.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102979"},"PeriodicalIF":9.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression","authors":"Lan Luo ,&nbsp;Yonglin Zhang ,&nbsp;Li Zhang ,&nbsp;Senguo Yang ,&nbsp;Tian Zhou ,&nbsp;Ke Luo ,&nbsp;Shu Liu","doi":"10.1016/j.ctrv.2025.102970","DOIUrl":"10.1016/j.ctrv.2025.102970","url":null,"abstract":"<div><div>Ovarian function suppression (OFS) is extensively acknowledged for its efficacy and benefits in the management of breast cancer among premenopausal women. While gonadotropin-releasing hormone agonists (GnRHa) serve as the fundamental component of OFS, a subset of patients experience incomplete estrogen suppression, leading to potential treatment failure and adverse outcomes. This review systematically examines ovarian escape (OE) during GnRHa treatment in premenopausal women with hormone receptor-positive (HR+) breast cancer and explores potential risk factors along with the underlying mechanisms. Discrepancies in defining menopausal status and assay variability complicate OE diagnosis; however, early detection and intervention can mitigate the risk of treatment failure. Current guidelines lack standardized guidelines for hormone monitoring, underscoring the need for personalized strategies to optimize OFS efficacy and mitigate risks. Further research is warranted to elucidate OE mechanisms and refine therapeutic approaches. By proposing evidence-based management strategies, this work advances personalized OFS approaches tailored to high-risk populations.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102970"},"PeriodicalIF":9.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective","authors":"Saby George ,&nbsp;Maria T. Bourlon ,&nbsp;Michael J. Overman ,&nbsp;Matt Dixon ,&nbsp;Karishma Shelley ,&nbsp;Kristen J. Markus ,&nbsp;Rachel M. Kewley ,&nbsp;Sophie I. Pope ,&nbsp;Laurence Albigès","doi":"10.1016/j.ctrv.2025.102974","DOIUrl":"10.1016/j.ctrv.2025.102974","url":null,"abstract":"<div><div>Subcutaneous (SC) formulations of oncology therapies offer a potentially less time-consuming and more convenient alternative to intravenous (IV) administration. However, exploring the potential benefits of SC over IV administration from a broader perspective is necessary to understand the larger-scale impact. In this systematic literature review (SLR), we evaluated the efficacy, pharmacokinetics/pharmacodynamics (PK/PD), safety, and patient and healthcare provider (HCP) preference for SC/IV oncology therapies, along with differences in patient outcomes, costs, and time requirements. The SLR was conducted in January 2019 and updated in May 2023, and included 169 publications. Studies providing comparative results between IV and SC formulations regarding clinical, economic, and patient outcomes were included. The focus was anticancer therapies for which both IV and SC formulations are being developed in phase 3 clinical trials, or are regulatory approved. SC administration was associated with savings in HCP time and patient chair time. Direct and indirect cost-savings were also observed. Increased treatment satisfaction and patient/HCP preference was reported with SC administration, as was improved caregiver productivity. The relative tolerability of SC and IV formulations for oncology drugs was similar; however, a higher incidence of injection-site reactions was reported with SC administration. Overall survival, PK/PD, and overall response rate results were comparable between IV and SC administration. This SLR demonstrates that SC and IV administration had comparable efficacy, PK/PD, and tolerability profiles, with SC administration associated with cost and time savings, and generally preferred by patients and HCPs. Therefore, SC administration of oncology therapies may offer advantages over IV administration.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102974"},"PeriodicalIF":9.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144513968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis” [Cancer Treat. Rev. 133 (2025) 102882]","authors":"Isabella Michelon ,&nbsp;Caio E.R. Castro ,&nbsp;Thiago Madeira ,&nbsp;Maria Inez Dacoregio ,&nbsp;Carlos Stecca ,&nbsp;Leonardo R. Soares ,&nbsp;Anwaar Saeed ,&nbsp;Maysa Vilbert ,&nbsp;Ludimila Cavalcante","doi":"10.1016/j.ctrv.2025.102994","DOIUrl":"10.1016/j.ctrv.2025.102994","url":null,"abstract":"","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102994"},"PeriodicalIF":10.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paving the path ForwARd: Advances and challenges in androgen receptor targeting in breast cancer","authors":"Nithya Sridhar ,&nbsp;Toshiaki Iwase ,&nbsp;Xuemei Xie ,&nbsp;Jangsoon Lee ,&nbsp;Senthil Damodaran ,&nbsp;Naoto T. Ueno","doi":"10.1016/j.ctrv.2025.102958","DOIUrl":"10.1016/j.ctrv.2025.102958","url":null,"abstract":"<div><div>The role of androgen receptors (AR) in breast cancer is crucial for preclinical and clinical research. While AR-targeted therapy is a standard treatment for prostate cancer, the application of this therapeutic strategy to breast cancer has not been established. Indeed, AR is expressed in around 60–90% of breast cancers, making it imperative that we learn more about its prognostic and predictive impacts and targeting potential in breast cancer. Over the past decade, AR-targeted therapies ─ including AR antagonists and selective AR modulators ─ have shown promise in breast cancer treatment. However, an incomplete understanding of AR’s role across breast cancer subtypes hinders clinical application. The lack of standardized AR expression thresholds further complicates patient selection, underscoring the urgent need for biomarker-driven strategies to optimize AR-targeted approaches in breast cancer. In this review, we provide an overview of a clinical perspective of AR in breast cancer by discussing AR biology, AR as a biomarker, and AR-targeted therapy development. We present our review with a particular emphasis on the distinct roles of AR in ER-positive (ER+) and ER-negative (ER-) breast cancer subtypes. Finally, the paper addresses the hurdles that have impeded the development of a robust clinical landscape for AR-targeted therapies and possible solutions for overcoming these challenges.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"138 ","pages":"Article 102958"},"PeriodicalIF":9.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis","authors":"Joseph R. Habib ,&nbsp;Asad Saulat Fatimi ,&nbsp;Omar Mahmud ,&nbsp;Ingmar F. Rompen ,&nbsp;Benedict Kinny-Köster ,&nbsp;Lois A. Daamen ,&nbsp;Jin He ,&nbsp;I. Quintus Molenaar ,&nbsp;Marco Del Chiaro ,&nbsp;Christopher L. Wolfgang ,&nbsp;Ammar A. Javed ,&nbsp;Marc G. Besselink ,&nbsp;for the PANC-PALS Consortium","doi":"10.1016/j.ctrv.2025.102969","DOIUrl":"10.1016/j.ctrv.2025.102969","url":null,"abstract":"<div><h3>Introduction</h3><div>The management of intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer is extrapolated from pancreatic intraepithelial neoplasm (PanIN)-derived pancreatic cancer. However, these cancers are biologically and clinically distinct and evidence regarding the role of adjuvant therapy (AT) is unclear. The aim of this systematic review and meta-analysis was to consolidate current evidence regarding survival benefit of AT for IPMN-derived pancreatic cancer.</div></div><div><h3>Methods</h3><div>Systematic searches of the PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL databases were performed from inception to February 2nd, 2025. Studies that reported survival analyses comparing AT versus surgery alone for resected IPMN-derived pancreatic cancer were included. Risk of bias was assessed using the Newcastle-Ottawa scale. Hazard ratios were pooled using generic inverse-variance random-effects models.</div></div><div><h3>Results</h3><div>A total of 26 studies were included in this review. All studies were observational and 16 had low risk of bias while 10 had high risk of bias. AT was not associated with an OS benefit on pooled multivariable analysis (HR: 0.78 [0.47, 1.28]) in the total population. In subgroups of patients with pathology node-positive (pN1 or pN2) disease, advanced T-stage and overall AJCC tumor stage, elevated CA19-9 (&gt;37 IU), and poor grade of differentiation, AT was associated with OS benefit.</div></div><div><h3>Conclusions</h3><div>Current data suggests that routine AT after resection of IPMN-derived pancreatic cancer is not associated with an OS benefit and may constitute overtreatment. However, patients with high-risk features such as large or high-grade tumors, nodal disease, and elevated CA19-9 may benefit from AT.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"138 ","pages":"Article 102969"},"PeriodicalIF":9.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis","authors":"Ye Yuan ,&nbsp;Xin Long ,&nbsp;Mengya Wei ,&nbsp;Li Chen ,&nbsp;Ji Zhang ,&nbsp;Xumei Liu","doi":"10.1016/j.ctrv.2025.102975","DOIUrl":"10.1016/j.ctrv.2025.102975","url":null,"abstract":"<div><h3>Introduction</h3><div>Direct comparisons between nab-paclitaxel and solvent-based taxanes are scarce, with inconsistent results from mostly retrospective studies. High-level evidence comparing their efficacy in HER2-positive breast cancer remains lacking. Our study represents the first systematic review and <em>meta</em>-analysis to directly compare the long-term and short-term efficacy and safety of nab-paclitaxel versus solvent-based paclitaxel in combination with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.</div></div><div><h3>Methods</h3><div>We performed a comprehensive literature search in PubMed, Embase, the Cochrane Library, CNKI, Wan Fang, and VIP databases to identify relevant studies published up to February 10, 2025. The search focused on studies involving patients with HER2-positive breast cancer who had not undergone prior treatments for their condition. These studies compared neoadjuvant therapies using either nab-paclitaxel-based chemotherapy (Nab-p arm) or solvent-based paclitaxel-based chemotherapy (Sb-p arm), both combined with pertuzumab and trastuzumab. The primary outcomes measured were event-free survival, disease-free survival, overall survival, and total pathological complete response. Secondary outcomes included objective response rate and adverse events. The quality of evidence was assessed using the GRADE methodology.</div></div><div><h3>Results</h3><div>A total of six studies, including 3 RCTs, 1 prospective cohort study and 2 real-world studies, involving 1556 patients were included. The Nab-p arm demonstrated numerically more favorable EFS, DFS compared to the Sb-p arm. There was no significant difference in OS between the Nab-p arm and the Sb-p arm. The Nab-p arm showed significant improvements in pCR (RR: 1.18, 95 % CI: 1.08–1.29, <em>p</em> &lt; 0.001), pCR (with only RCTs) (RR: 1.13, 95 % CI: 1.03–1.24, <em>p =</em> 0.009), and ORR (RR: 1.30, 95 % CI: 1.07–1.57, <em>p</em> = 0.007) compared to the Sb-p arm. The Nab-p arm showed a lower grade III/IV diarrhea rate (RR: 0.59, 95 % CI: 0.42–0.83, <em>p</em> = 0.003), grade III/IV thrombocytopenia rate (RR: 0.46, 95 % CI: 0.24–0.89, <em>p</em> = 0.02), grade I/II allergic reactions rate (RR: 0.60, 95 % CI: 0.46–0.78, <em>p</em> &lt; 0.001) and grade III/IV allergic reactions rate (RR: 0.33, 95 % CI: 0.14–0.82, <em>p</em> = 0.02), compared to the Sb-p arm. The Nab-p arm showed a higher grade I/II neuropathy rate (RR: 1.21, 95 % CI: 1.12–1.30, <em>p</em> &lt; 0.001) and grade III/IV neuropathy rate (RR: 2.61, 95 % CI: 1.23–5.52, <em>p</em> = 0.001), compared to the Sb-p arm.The outcome of pCR had moderate-quality evidence and the outcome of pCR (with only RCTs) had high-quality evidence.</div></div><div><h3>Conclusions</h3><div>Nab-paclitaxel exhibits short-term efficacy advantages over paclitaxel, but no significant long-term benefits. The two regimens have different safety profile.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"138 ","pages":"Article 102975"},"PeriodicalIF":9.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clearer Horizons: The latest advances in clear cell ovarian cancer treatment","authors":"Felix Blanc-Durand ,&nbsp;Natalie Ngoi ,&nbsp;Diana Lim ,&nbsp;Isabelle Ray-Coquard ,&nbsp;David SP Tan","doi":"10.1016/j.ctrv.2025.102977","DOIUrl":"10.1016/j.ctrv.2025.102977","url":null,"abstract":"<div><div>This review aims to consolidate the current understanding of Clear Cell Ovarian Carcinoma (CCOC), a rare yet distinct subtype of epithelial ovarian cancer. CCOC exhibits unique epidemiological, clinical and molecular features, being one of the most frequent subtypes in East Asia, often diagnosed at an early stage and frequently affecting younger women.</div><div>Its hallmark characteristics include high resistance to conventional chemotherapy, poor prognosis in advanced stage and a molecular profile distinct from high-grade serous histotype. Specifically, CCOC is characterized by a low prevalence of <em>TP53</em> mutations, <em>BRCA1/2</em> mutations and homologous-recombination deficiency, but a high frequency of <em>ARID1A</em>, along with other SWI/SNF alterations, and <em>PIK3CA</em> mutations, both of which represent promising therapeutic targets.</div><div>Despite the absence of validated therapies for CCOC so far, significant advancements in preclinical research and emerging clinical strategies including immunotherapy combinations offer hope for improved outcomes. Given the rarity of this cancer type, collaborative research and global partnerships have enabled robust studies and the implementation of trials with innovative personalized therapeutic approaches.</div><div>The objective of this report is to explore the epidemiology, clinical and molecular characteristics, current standard of care and evolving therapeutic strategies for CCOC patients. It will not only highlight the progress made so far, but most importantly identifies critical research priorities to optimizing patient outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"138 ","pages":"Article 102977"},"PeriodicalIF":9.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}